FAAP

Philadelphia-area health organizations form Regional Coalition to Eliminate Race-Based Medicine

Retrieved on: 
Thursday, August 10, 2023
Children's Hospital of Philadelphia, Independence Blue Cross, Trinity Health Mid-Atlantic, IBC, Pediatrics, Temple University Hospital, Temple University, St. Christopher's Hospital for Children, Main Line Health, Hospital, Nemours Children's Hospital, Delaware, Health equity, Health, Saint Christopher, Senior, Virtua Health, FAAP, Comfort, Regional Coalition for Clean Rivers and Streams, Jefferson Health, Population health, Patient, Protocol, Heal, JD, Inclusion, Racism, Region, MPH, Trinity Health, Disease, Vaccine, Nursing, Independence, Women & Health, Child, Doctor of Philosophy, MD, Medicine

Jefferson Health is proud to be a part of the Regional Coalition to Eliminate Race-Based Medicine in our effort to eliminate race as a factor in our clinical decision-making tools," said Dwight W. McBee, executive vice president and chief experience officer at Jefferson Health.

Key Points: 
  • Jefferson Health is proud to be a part of the Regional Coalition to Eliminate Race-Based Medicine in our effort to eliminate race as a factor in our clinical decision-making tools," said Dwight W. McBee, executive vice president and chief experience officer at Jefferson Health.
  • "As a leading multi-state children's health system, Nemours Children's Health is well-poised to act as a force-multiplier for health equity.
  • "With our continued focus on delivering safe, high-quality, and equitable care, Main Line Health is proud to join the Regional Coalition to Eliminate Race-Based Medicine.
  • The coalition brings together the region's leading health care organizations to address longstanding racial inequities in how medical decisions are made.

MGMA Report Reveals Medical Groups' Efforts to Overcome Labor Shortages and Inflation Pains

Retrieved on: 
Thursday, June 29, 2023
The Harley Medical Group, Medicine, Travel, Nursing, COVID-19, FACMPE, Labour, Organization, FAAP, Hospital, MMM, Benchmarking, Ampere-hour, Cryptocurrency, Retail, Management, MD

ENGLEWOOD, Colo., June 29, 2023 /PRNewswire/ -- New research from the Medical Group Management Association (MGMA) reveals that medical group leaders continue to make bold changes to address persistent staffing hurdles and rising labor expenses to meet growing patient demand for care. The 2023 MGMA Management and Staff Compensation data set, based on 2022 data, includes insights from more than 157,000 management and staff positions from nearly 3,000 organizations. 

Key Points: 
  • The 2023 MGMA Management and Staff Compensation data set, based on 2022 data, includes insights from more than 157,000 management and staff positions from nearly 3,000 organizations.
  • While inflationary growth is slowing in 2023, salary costs continue on an upward trajectory.
  • Hourly rates for clinical and nursing staff continued to increase annually, keeping pace with the annual total compensation increases.
  • With vital insights to empower leaders to evolve their recruitment and retention efforts, the report highlights labor considerations and strategies to address ongoing challenges in an ever-shifting healthcare environment.

Understood.org Partners With American Academy of Pediatrics to Empower Families With Children Who Learn and Think Differently

Retrieved on: 
Thursday, June 29, 2023
Learning, Partnership, Education, Parent, Pediatrics (journal), ADHD, American Academy, AAP, Language, Thought, Organization, School, Physician, Child, Dyslexia, Mental health, Neurodiversity, Toy, Nursing, Pediatrics, FAAP, Understanding, MD

Families of kids who learn and think differently often struggle to find resources and a supportive community.

Key Points: 
  • Families of kids who learn and think differently often struggle to find resources and a supportive community.
  • Annual pediatricians' visits — often required by schools — provide a unique opportunity for pediatricians and families to recognize and support children with learning and thinking differences.
  • "We're excited to be partnering with the American Academy of Pediatrics to help physicians support families to understand, manage, and embrace their child's unique strengths."
  • "Our goal is to facilitate critical interaction and collaboration between families and pediatricians," said Sandy Chung, MD, FAAP, president of the American Academy of Pediatrics.

ZYUS Life Sciences Strengthens Board of Directors with the Appointment of Wayne Brownlee

Retrieved on: 
Thursday, June 29, 2023
Cannabis, Alternative Medicine, Natural Resources, Health, Pharmaceutical, Saskatchewan Order of Merit, Bachelor of Science in Human Biology, University of Toronto Faculty of Medicine, Business development, Cannabis Act, TSX Venture Exchange, University, University of Saskatchewan, Business, Public policy, Crown, Nutrien, Associate, Government, PotashCorp, Organization, Business administration, FAAP, Privatization, Retirement, Acquisition, Division, Hospital, CFO, Knowledge, Entrepreneurship, FRCPC, Chartered Professional Accountant, Health Canada, ICL Group Ltd., Management, Science, SQM, MD, Medicine

ZYUS Life Sciences Corp. ("ZYUS" or the “Company”) (TSX-V: ZYUS), a Canadian-based life sciences company leading scientific research and global development of innovative cannabinoid-based pharmaceutical drug products, is pleased to announce that Wayne Brownlee, former Vice-President and Chief Financial Officer (“CFO”) of both Potash Corporation of Saskatchewan Inc. (“PotashCorp”) and Nutrien Ltd. (“Nutrien”), has agreed to accept an appointment to ZYUS’ Board of Directors.

Key Points: 
  • ZYUS Life Sciences Corp. ("ZYUS" or the “Company”) (TSX-V: ZYUS), a Canadian-based life sciences company leading scientific research and global development of innovative cannabinoid-based pharmaceutical drug products, is pleased to announce that Wayne Brownlee, former Vice-President and Chief Financial Officer (“CFO”) of both Potash Corporation of Saskatchewan Inc. (“PotashCorp”) and Nutrien Ltd. (“Nutrien”), has agreed to accept an appointment to ZYUS’ Board of Directors.
  • Mr. Brownlee brings a wealth of knowledge, experience and expertise to his new role with ZYUS.
  • In 1989, Mr. Brownlee joined PotashCorp when it was a Crown corporation and was a catalyst for the expansion and development throughout its acquisition activity.
  • “We are extremely pleased to welcome Wayne Brownlee to ZYUS’ Board of Directors,” said Brent Zettl, President and Chief Executive Officer of the Company.

Children’s Hospital Los Angeles Names Sucheta Joshi, MD, MS, FAAP, FAES as Incoming Medical Director of Comprehensive Epilepsy Program

Retrieved on: 
Thursday, June 29, 2023
Health, Hospitals, Epilepsy, Seth, Telehealth, Bachelor, University of Mumbai, University, MBBS, National Association of Epilepsy Centers, Bachelor of Medicine, Bachelor of Surgery, CHLA, Policy, Advisory Committee, Pediatrics (journal), King Edward Memorial Hospital and Seth Gordhandas Sunderdas Medical College, Service, American Academy, Multimedia, AAP, Research, Neurology, Montreal Neurological Institute and Hospital, Smoking and Health: Report of the Advisory Committee to the Surgeon General of the United States, Stanford University School of Medicine, University of Michigan School of Dentistry, Michigan Medicine, Pediatric Neurology, Public health, Committee, Medical director, Division, Children's Hospital Los Angeles, FAES, University of Michigan School of Public Health, National Association, Nursing, Pharmaceutical industry, Pediatrics, FAAP, MD, Medicine

View the full release here: https://www.businesswire.com/news/home/20230629162494/en/

Key Points: 
  • View the full release here: https://www.businesswire.com/news/home/20230629162494/en/
    Sucheta Joshi, MD, MS, FAAP, FAES, has been named as incoming Medical Director of the Neurological Institute Comprehensive Epilepsy Program at Children’s Hospital Los Angeles (CHLA).
  • She most recently has served as Service Chief of Pediatric Neurology and Medical Director of Pediatric Epilepsy at Michigan Medicine, the academic medical center of the University of Michigan, where she launched a complex epilepsy clinical program and an inpatient pediatric epilepsy service.
  • In her new role, Dr. Joshi will lead and expand the Comprehensive Epilepsy Program at CHLA and will grow programs such as telehealth, precision health trials, adult transition, team-based clinics and surgical epilepsy.
  • Joshi’s leadership will help us reach the full potential of our Comprehensive Epilepsy Program.

Renaye James Healthcare Advisors Becomes a New HRSA National Training and Technical Assistance Partner

Retrieved on: 
Tuesday, June 27, 2023
HRSA, National Center for Healthcare Leadership, Health Resources and Services Administration, Education, MBA, PMP, FAAP, MD, Patient, Population health, Nursing

Columbia, Maryland--(Newsfile Corp. - June 27, 2023) - Renaye James Healthcare Advisors is proud to announce that it has been awarded a Health Resources and Services Administration (HRSA) Bureau of Primary Healthcare National Training and Technical Assistance Partner (NTTAP) cooperative agreement to provide nationwide training and technical assistance to health centers.

Key Points: 
  • Columbia, Maryland--(Newsfile Corp. - June 27, 2023) - Renaye James Healthcare Advisors is proud to announce that it has been awarded a Health Resources and Services Administration (HRSA) Bureau of Primary Healthcare National Training and Technical Assistance Partner (NTTAP) cooperative agreement to provide nationwide training and technical assistance to health centers.
  • We look forward to working with the other NTTAPs to bring valuable resources to our nation's health centers," said Jenene R. Washington, MD, MBA, FAAP, PCMH-CCE, PMP, Founder and CEO of Renaye James Healthcare Advisors .
  • Being selected as an NTTAP for this area provides the opportunity for Renaye James Healthcare Advisors to work closely with health centers to promote lasting changes.
  • Renaye James Healthcare Advisors has a comprehensive plan to provide training and technical assistance.

Childhood Diabetes Screening Shown to Predict Future Diabetes-Related Complications

Retrieved on: 
Saturday, June 24, 2023
NIDDK, Ophthalmoscopy, Glycated hemoglobin, ACR, Aneurysm, Obesity, Diabetes, Kidney, Diabetes Care, Eye disease, Research, PG, Southwestern United States, Bangladesh Technical Education Board, Glycemia, Retinopathy, FAAP, Blood, Bleeding, Guideline, Risk, SAN, American Diabetes Association, American Indians, Albuminuria, Overweight, Digestive, Prediabetes, ADA, T2D, National Institute of Diabetes and Digestive and Kidney Diseases, NIH, Kidney disease, Syndrome, Dietary supplement, MD

SAN DIEGO, June 23, 2023 /PRNewswire/ -- New research from the National Institutes of Health (NIH) found that blood glucose levels obtained at childhood examinations predicted future diabetes related complications such as kidney disease (nephropathy) and eye disease (retinopathy). The findings were presented at the American Diabetes Association® (ADA) 2023 Scientific Sessions in San Diego, CA and were simultaneously published in the Diabetes Care journal.

Key Points: 
  • The findings were presented at the American Diabetes Association® (ADA) 2023 Scientific Sessions in San Diego, CA and were simultaneously published in the Diabetes Care journal.
  • This data comes at a time when the United States is experiencing a significant rise in obesity induced youth-onset type 2 diabetes (T2D).
  • As a result, ADA has recommended risk-based screening for prediabetes and/or diabetes in asymptomatic children with overweight or obesity by pediatric health care providers.
  • The study sought to evaluate the association of higher levels of glycemia during childhood with future microvascular complications in American Indian children – a population that is twice as likely to have diabetes than white individuals.

Breakthrough Solution for Fragile Skin: Covalon’s IV Clear® Dressing Recommended by Physicians at a Top 10 U.S. Children’s Hospital and Epidermolysis Bullosa Center of Excellence

Retrieved on: 
Tuesday, June 13, 2023
Oncology, Medical Supplies, Health, Medical Devices, Infectious Diseases, Hospitals, Biotechnology, Infection, Connective tissue, CHCO, IV, Prevalence, Tears, CLABSI, Skin, Kate Brookes-Peterson, COV, DRS, Multimedia, Research, Catheter, Marketing, Incidence, FAAP, MD, Patient, Physician, Risk, Acrylic, Epidermolysis bullosa, Blister, The Company, International Anesthesia Research Society, Fluid mechanics, FDA, EB, Trauma, SVP, Anesthesiology, Safety, Medical device, Janosy Hill

View the full release here: https://www.businesswire.com/news/home/20230613612362/en/

Key Points: 
  • View the full release here: https://www.businesswire.com/news/home/20230613612362/en/
    Covalon's IV Clear® is the world's only dual antimicrobial silicone adhesive vascular access dressing.
  • (Photo: Business Wire)
    EB, sometimes known as “Butterfly Skin”, is a little-known skin disorder with a prevalence of 1 in 20,000 births.
  • There is no cure to the debilitating connective tissue disorder that causes extremely fragile skin prone to blisters and tears from minor friction.
  • EB patients often require surgical procedures, and securement of intravenous (IV) catheters and peripheral nerve catheters on EB patients present major challenges to anesthesiologists.

"ResBiotic Publishes Promising Safety and Efficacy Findings from Clinical Trial Study of resB® Lung Support Supplement"

Retrieved on: 
Tuesday, June 13, 2023
MCN, JM, Frontiers, The Journal of Clinical Psychiatry, Pediatrics, LD, International Workshop on Lung Health, Science, FAAP, Clinical trial, Journal, Growth, Probiotic, Dietary supplement, Nutrition, RD, MD

BIRMINGHAM, Ala., June 12, 2023 /PRNewswire/ -- ResBiotic Nutrition Inc (ResBiotic) announced today that its latest peer-reviewed clinical trial featuring resB® Lung Support has been published in Frontiers in Nutrition. The study, titled "Clinical Trial of a Probiotic and Herbal Supplement for Lung Health," yielded significant results, including improvements in lung functions and in quality of life scores in participants. Overall, most participants were highly likely to recommend resB®. resB® Lung Support, as a product target anyone concerned about their respiratory or lung health. In addition, users of resB® see significant gut health and immune benefits similar to other high potency probiotics.

Key Points: 
  • BIRMINGHAM, Ala., June 12, 2023 /PRNewswire/ -- ResBiotic Nutrition Inc (ResBiotic) announced today that its latest peer-reviewed clinical trial featuring resB® Lung Support has been published in Frontiers in Nutrition.
  • The study, titled " Clinical Trial of a Probiotic and Herbal Supplement for Lung Health ," yielded significant results, including improvements in lung functions and in quality of life scores in participants.
  • resB® Lung Support, as a product target anyone concerned about their respiratory or lung health.
  • Adding, "Each ingredient in resB® Lung Support has been validated and tested for efficacy in several studies, and we are launching similar science backed products to our portfolio this year".

Taysha Gene Therapies Announces First Patient Dosed with TSHA-102 in the REVEAL Phase 1/2 Trial Under Investigation for the Treatment of Rett Syndrome

Retrieved on: 
Monday, June 5, 2023
Communication, Index, FRCP, Central nervous system, Pediatrics, VG, Clinical trial, MECP2, Rett syndrome, Neuroscience, Gene expression, AAV, CNS, Associate, CHU, FAAP, Patient, Child, MAD, MTD, Principal, Safety, Disease, Pharmaceutical industry, Rett

DALLAS, June 05, 2023 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (Nasdaq: TSHA), a clinical-stage gene therapy company focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the central nervous system (CNS), today announced that the first patient has been dosed with TSHA-102 in the Phase 1/2 REVEAL trial evaluating the safety and preliminary efficacy of TSHA-102 in adult patients with Rett syndrome. TSHA-102 is a self-complementary intrathecally delivered AAV9 investigational gene transfer therapy that utilizes a novel miRNA-Responsive Auto-Regulatory Element (miRARE) platform designed to regulate cellular MECP2 expression. The study is being conducted at CHU Sainte-Justine, the Université de Montréal mother and child university hospital centre in Montreal, Canada.

Key Points: 
  • The study is being conducted at CHU Sainte-Justine, the Université de Montréal mother and child university hospital centre in Montreal, Canada.
  • This is a significant milestone that furthers our quest to bring a potentially transformational gene therapy to patients and families living with Rett syndrome.
  • The dosing of the first patient in this important clinical trial represents a critical advancement in evaluating the potential of gene therapy for Rett syndrome.
  • We’re pleased to collaborate with Taysha Gene Therapies in an effort to bring a gene therapy treatment that could meaningfully change the lives of patients and their caregivers.”